Short-term safety evaluation of intraperitoneal chemotherapy with Raltitrexed for colorectal cancer

Abstract

Objective To evaluate of the recent safety and feasibility of intraoperative intraperitoneal chemotherapy with Raltitrexed for colorectal cancer patients. Methods The clinical data of colorectal cancer patients undergoing surgery from the National Cancer Center from July 2017 to October 2018 were retrospectively analyzed. 80 colorectal cancer patients who underwent radical surgery were divided into two groups. The Raltitrexed group (40 patients), who received intraoperative intraperitoneal perfusion chemotherapy with Raltitrexed and the control group (40 patients), who did not receive intraoperative intraperitoneal perfusion chemotherapy. Analysis of the recent safety differences between the two groups in terms of postoperative complications, liver and kidney function, hematological toxicity, and time of gastrointestinal function recovery. Results There was no significant differences in the incidence of postoperative complications, liver and kidney function, blood toxicity and recovery time of gastrointestinal function between the two groups (all P>0.05). Conclusions Intraoperative perfusion with Raltitrexed for patients with colorectal cancer has good safety and tolerability, and does not increase postoperative complications. Key words: Colorectal neoplasms; Surgery; Raltitrexed; Intraperitoneal perfusion chemotherapy; Safety